173 related articles for article (PubMed ID: 15525221)
1. NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.
Tomera KM
Expert Rev Mol Diagn; 2004 Nov; 4(6):783-94. PubMed ID: 15525221
[TBL] [Abstract][Full Text] [Related]
2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
3. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
4. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
6. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
9. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
10. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.
Lotan Y; Elias K; Svatek RS; Bagrodia A; Nuss G; Moran B; Sagalowsky AI
J Urol; 2009 Jul; 182(1):52-7; discussion 58. PubMed ID: 19450825
[TBL] [Abstract][Full Text] [Related]
12. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.
Lotan Y; Shariat SF;
BJU Int; 2008 Jun; 101(11):1362-7. PubMed ID: 18284410
[TBL] [Abstract][Full Text] [Related]
13. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
14. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
Terrell JD; Elias KJ; Sagalowsky AI; Lotan Y
Int Braz J Urol; 2011; 37(6):706-11. PubMed ID: 22234001
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
16. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
18. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic test for bladder cancer: the NMP22®].
Saint F; Quintens H; Roupret M; Amsellem-Ouazana D; Mazerolles C; Wallerand H; Bernardini S; Guy L; Soulié M; Pfister C;
Prog Urol; 2011 Apr; 21(4):245-9. PubMed ID: 21482397
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]